A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
Public ClinicalTrials.gov record NCT02340975. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Study identification
- NCT ID
- NCT02340975
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 114 participants
Conditions and interventions
Interventions
- MEDI4736 Biological
- MEDI4736 + tremelimumab Biological
- Tremelimumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2015
- Primary completion
- Apr 28, 2019
- Completion
- Apr 28, 2019
- Last update posted
- Jun 8, 2020
2015 – 2019
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | 90033 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | New Haven | Connecticut | 06520 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Baltimore | Maryland | 21231 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | New York | New York | 10116 | — |
| Research Site | Cleveland | Ohio | 44106 | — |
| Research Site | Portland | Oregon | 97213 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | Greenville | South Carolina | 29605 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02340975, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2020 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02340975 live on ClinicalTrials.gov.